Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XY0206 in Relapsed/Refractory AML
NCT04471064Phase 1Unknown
- Sponsor
- Yiling Pharmaceutical
- Start
- Sep 2020
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of XY0206 in acute myeloid leukemia (AML) (7 arms), sponsored by Yiling Pharmaceutical. Primary endpoints: Maximum Tolerable Dose, Dose Limiting Toxicity and 2 more. Status: unknown.
02
Drugs
XY0206
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04471064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04471064.